NexPoint Strategic Opportunities Fund
Change company Symbol lookup
Select an option...
NHF NexPoint Strategic Opportunities Fund
FUAPF Global Cannabis Applications Corp
GXG Global X MSCI Colombia ETF
ATMR Altimar Acquisition Corp II
AMD Advanced Micro Devices Inc
WST West Pharmaceutical Services Inc
PLBY Plby Group Inc
SVFA SVF Investment Corp

Company profile

NexPoint Strategic Opportunities Fund (the Trust), formerly NexPoint Credit Strategies Fund, is a non-diversified, closed-end management investment company. The Trust's objective is to provide both current income and capital appreciation. The Trust allocates its investments in public equities, private equity investments, collateralized loan obligation (CLOs) debt, high yield bonds, syndicated floating rate bank loans, real estate assets, CLO equity, non-traditional yield oriented investments and hedge exposure where necessary. The Trust invests in various sectors, which include chemicals, energy, gaming and leisure, housing, media and telecommunications, real estate investment trust, healthcare, asset-backed securities, and information technology. NexPoint Advisers L.P. serves as the investment adviser to the Trust.

Closing Price
Day's Change
-0.17 (-1.18%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Exact stock surges as changes to Pfizer's sales agreement a 'positive,' analyst says

2:30 pm ET September 15, 2021 (MarketWatch)

Shares of Exact Sciences Corp. (EXAS) rallied 8.0% in afternoon trading Wednesday, after the molecular diagnostics company said it taking over the selling of its Cologuard at-home colon cancer screening test from Pfizer Inc. (PFE), and said it was discussing with Pfizer "material changes" to their promotion agreement. The company said it learned in late August that Pfizer cut the sales positions supporting its business tasked with selling Cologuard, so Exact offered those displaced sales representatives jobs. Exact said it added about 400 sales reps in September, bringing the total to more than 850 sales reps. The company said it expects those reps to be "more productive" than when they were at Pfizer, since they will be fully focused on selling Cologuard, and because Pfizer was not making in-personal sales calls in 41 states because of its COVID-19 policies, which were different than Exact's policies. Analyst Bruce Jackson at Benchmark reiterated his buy rating and $165 price target on Exact's stock, saying the disclosed changes were, "Overall, positive for Exact." The stock has dropped 14.5% over the past three months, while the S&P 500 has gained 5.4%.

-Tomi Kilgore


(END) Dow Jones Newswires

September 15, 2021 14:30 ET (18:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.